Sun Pharmaceutical Industries

Diversified pharma

SUNPHARMA · NSE · India

Public Market Listing

SUNPHARMANSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Sun Pharmaceutical Industries are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
4Approved
1Phase 3 / Filed
1Phase 1–2 / Early
9Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
Glucocorticoid receptor
Inflammatory Bowel Disease
Crohn's Disease
Approved
Iron-replacement therapy delivered via dialysateSmall molecule
Chronic Kidney DiseaseIron Deficiency Anemia
Approved
GABA-A receptorSmall molecule
Epilepsy
Approved
IL-23 p19Monoclonal antibody
Psoriatic ArthritisPsoriasis
Lerodalcibep(Lerochol)
Phase 3
PCSK9Protein / enzyme therapeutic
Atherosclerotic Cardiovascular Disease
Phase 2
GLP-1 receptorPeptide
ObesityType 2 Diabetes

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
UtreglutidePhase 2Type II Diabetes Mellitus
Est. primary completion 2027-04 · NCT07282743 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Lerodalcibep · LerocholPhase 3Familial Hypercholesterolemia - Heterozygous
Est. primary completion 2028-07-31 · NCT07102511 · CT.gov ↗
What to watch
December 2028 (1)
tildrakizumab · IlumyaPhase 3Psoriatic Arthritis
Est. primary completion 2028-12 · NCT04991116 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Lerodalcibep · LerocholPhase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2031-07-31 · NCT07775339 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026FDA action datetildrakizumabILUMYA psoriatic arthritis FDA action date October 29, 2026
US, FDA · Sun Pharmaceutical Industries · Source ↗
29 October 2026ApprovaltildrakizumabFDA approves ILUMYA in active psoriatic arthritis
US, FDA · Source ↗
26 June 2026Filing acceptedLerodalcibepNMPA accepts the LEROCHOL (lerodalcibep) BLA for hypercholesterolemia
CN, NMPA · Everest Medicines · Source ↗
16 March 2026Filing acceptedtildrakizumabFDA accepts ILUMYA sBLA for psoriatic arthritis
US, FDA · Sun Pharmaceutical Industries · Source ↗
21 July 2025Topline resulttildrakizumabINSPIRE-1 and INSPIRE-2 Phase 3 met primary endpoint
Sun Pharmaceutical Industries · Source ↗

Financial reports

Quarterly & interim (3)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1$1.5B$91M$1.2B—report ↗

Sun Pharmaceutical Industries reported revenue of $1,497.02M, down 74.4% YoY, R&D spend of $91.31M, down 75.8% YoY, and cash and equivalents of $1,201.86M for Q1 2025.

Figures only: this period's report disclosed no narrative text

View 2 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q4$1.6B$98M——report ↗
2024-Q2$1.5B$93M——report ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$6.6B$401M$1.0B—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.2B$373M$1.2B—report ↗
2024-FY$5.9B$378M$1.1B—report ↗
2023-FY$5.4B$286M$563M—report ↗
2022-FY$5.2B$286M$595M—report ↗
2021-FY$4.5B$284M$854M—report ↗